Coronary Embolism and Myocardial Infarction in a Transgender Male Undergoing Hormone Therapy: A Case Report and Review of the Literature.

Following major thromboembolic cardiovascular events, we believe that transgender males treated with high-dose testosterone therapy should receive oral anticoagulation, preferably with a DOAC, especially keeping in mind that the discontinuation of the hormone therapy is not always possible due to the various underlying psychosocial factors.